Merck Lands Cancer Fighter Harpoon Therapeutics For $680M
Merck has entered into an agreement to acquire Harpoon Therapeutics, a cancer immunotherapy company founded eight years ago, for $23 per share in cash for an approximate total equity value of...To view the full article, register now.
Already a subscriber? Click here to view full article